Source 1review2026MED
Toolkit/HBV-directed CARs
HBV-directed CARs
Also known as: HBsAg-directed CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
High-signal enrichment leads were found primarily in PubMed/PMC and ClinicalTrials sources, with strongest support for HBV HBsAg-directed CARs. Explicitly supported related components/tools include HBV-directed binders/constructs (HBsAg, PreS1, 4D06, 4D08).
Usefulness & Problems
Why this is useful
This construct class refers to CAR-T designs directed against HBV antigens, especially HBsAg. The supplied evidence also names PreS1, 4D06, and 4D08 as related HBV-directed components.; designing HBV-targeted CAR recognition modules; targeting HBV surface antigens in CAR-T designs
Source:
This construct class refers to CAR-T designs directed against HBV antigens, especially HBsAg. The supplied evidence also names PreS1, 4D06, and 4D08 as related HBV-directed components.
Source:
designing HBV-targeted CAR recognition modules
Source:
targeting HBV surface antigens in CAR-T designs
Problem solved
It addresses the need for antigen-specific recognition of HBV-positive target cells in antiviral CAR-T design.; provides antigen-targeting strategies for HBV-directed CAR-T engineering
Source:
It addresses the need for antigen-specific recognition of HBV-positive target cells in antiviral CAR-T design.
Source:
provides antigen-targeting strategies for HBV-directed CAR-T engineering
Problem links
provides antigen-targeting strategies for HBV-directed CAR-T engineering
LiteratureIt addresses the need for antigen-specific recognition of HBV-positive target cells in antiviral CAR-T design.
Source:
It addresses the need for antigen-specific recognition of HBV-positive target cells in antiviral CAR-T design.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antigen-specific recognitionTarget processes
selectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator
It requires an HBV-binding recognition domain incorporated into a CAR construct. The payload does not provide further implementation details.; requires an HBV-directed recognition module such as an HBsAg- or PreS1-related binder
The supplied evidence does not establish how these designs handle broader translational issues such as persistence or safety.; the supplied payload does not provide detailed construct comparisons or validation outcomes
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review explicitly names gp350 and LMP1 as EBV CAR target leads, and names BRG01 as a gp350-targeted autologous CAR-T product in clinical development.
The review explicitly names HBsAg-related and PreS1-related HBV CAR strategies, including 4D06 and 4D08 as HBV-directed binder leads.
The review explicitly names VRC01, 3BNC117, and 10-1074 as HIV broadly neutralizing antibody-derived CAR binder leads.
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
The review explicitly names CCR5-locus knock-in and C34-CXCR4 as HIV-protective engineering features relevant to antiviral CAR-T design.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug hbv-directed-cars
High-signal enrichment leads were found primarily in PubMed/PMC and ClinicalTrials sources, with strongest support for HBV HBsAg-directed CARs. Explicitly supported related components/tools include HBV-directed binders/constructs (HBsAg, PreS1, 4D06, 4D08).
Source:
component summarysupports
The review explicitly names HBsAg-related and PreS1-related HBV CAR strategies, including 4D06 and 4D08 as HBV-directed binder leads.
Source:
design landscape summarysupports
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
Source:
Comparisons
Source-stated alternatives
The payload mentions TCR-T as a neighboring engineered T-cell modality relevant to HBV.
Source:
The payload mentions TCR-T as a neighboring engineered T-cell modality relevant to HBV.
Source-backed strengths
strong support in the supplied evidence for HBsAg-directed designs; multiple named HBV-related binders or target regions are explicitly listed
Source:
strong support in the supplied evidence for HBsAg-directed designs
Source:
multiple named HBV-related binders or target regions are explicitly listed
Compared with TCR-T
The payload mentions TCR-T as a neighboring engineered T-cell modality relevant to HBV.
Shared frame: source-stated alternative in extracted literature
Strengths here: strong support in the supplied evidence for HBsAg-directed designs; multiple named HBV-related binders or target regions are explicitly listed.
Relative tradeoffs: the supplied payload does not provide detailed construct comparisons or validation outcomes.
Source:
The payload mentions TCR-T as a neighboring engineered T-cell modality relevant to HBV.
Ranked Citations
- 1.